The Safety of Dapoxetine/Tadalafil Combination Therapy

Erectile Dysfunction Clinical Trial

Official title:

The Safety of Dapoxetine/Tadalafil Combination Therapy in Treatment of Men With Premature Ejaculation and Erectile Dysfunction

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03177746
• Other study ID #: NEU-10.16
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: December 31, 2022
• Est. completion date: October 14, 2023

Study information

• Verified date: May 2022
• Source: Neutec Ar-Ge San ve Tic A.S
• Contact: Neutec R&D
• Phone: 00902128505102
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of Dapoxetine/Tadalafil 30/20 mg film-coated tablet in the treatment of men with premature ejaculation and erectile dysfunction.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: October 14, 2023
• Est. primary completion date: January 14, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• 18-64 years old men,
• Participants must be heterosexual males and in a stable monogamous sexual relationship with a female partner for at least 6 months and will continue throughout the study,
• Clinical diagnosis of erectile dysfunction, IIEF score =21,
• Premature Ejaculation Diagnostic Tool (PEDT) score must be =11
• Patients with life-long PE and acquired PE according to the description of International Society for Sexual Medicine (ISSM) ,
• The patient and his partner must have sexual intercourse twice a week for the duration of the study,
• Commitment to comply with the study protocol,
• Patients who sign informed consent form (ICF).

Exclusion Criteria:

• History of medical events such as surgical interventions or neurologic conditions (e.g., multiple sclerosis), trauma, or infections that are associated with the development of symptoms of premature ejaculation (PE) and considered a potential cause of PE,
• Having genital abnormalities, except penile curvature unless not prevent sexual intercourse,
• Developed erectile dysfunction or premature ejaculation due to drug use or quit taking drugs,
• Any conditions that prevent sexual intercourse with partners
• History of epilepsy,
• Severe renal insufficiency,
• Liver disease,
• History of in last 6 months stroke, myocard infarction, cardiac insufficiency (New York Cardiovascular Associates (NYCA) phase II-IV), atrioventricular block or message disorder such as sick sinus syndrome, severe ischemic cardiac disease, syncope, unstable angina, life-threatening arrhythmia or hypotension,
• Non-Arteritic Anterior ischemic optic neuropathy,
• Patients who are not eligible to have sexual intercourse due to existing health problems,
• Autonomic neuropathy, retinitis pigmentosa, blood diseases, active peptic ulcer, abnormalities in ECG, severe systemic disease that cannot be controlled,
• Systolic/Diastolic blood pressure at rest <90/50 mmHg and 170/100 mmHg<
• History of allergy to Selective Serotonin Reuptake Inhibitor (SSRI) and phosphodiesterase inhibitor drugs,
• Continuing to use or quitted in last 3 months of Monoamine oxidase inhibitor (MAOI), Thioridazine, Serotonin Reuptake Inhibitor (SSRI), Selective-norepinephrine Reuptake Inhibitor (SNRI), Serotonergic drug/herbal product, tricyclic antidepressant and atypical antipsychotic drugs,
• Use of nitrates, alfa blockers, vasodilators, ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir, atazanavir, cimetidine, erythromycin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil, diltiazem, any kind of vasodilator, antiplatelet, anticoagulant, dapoxetine, phosphodiesterase 5 inhibitor, alcohol and stimulant drug,
• Patients on a different therapy (behavioral therapy or other drugs that are applied locally) for PE treatment
• During the study, the possibility of taking medication which may affect the study drug's pharmacokinetic/pharmacodynamic properties
• Patients who are defining symptoms of prostatitis clinically
• Thyroid hormone disorders

Related Conditions & MeSH terms

• Erectile Dysfunction
• Premature Birth
• Premature Ejaculation
• Safety Issues

Intervention

Drug:
• Dapoxetine/Tadalafil 30/20 mg film coated tablet
During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse. Study drug should not be used more than 1 tablet every 24 hours during the treatment.

Locations

Country	Name	City	State
Turkey	Okmeydani Training and Research Hospital Urology Dep.	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Neutec Ar-Ge San ve Tic A.S

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of safety of study drug	Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment	4 weeks
Secondary	Evaluation of change in Intra-vaginal Ejaculation Latency Time (IELT) compared to baseline	Intra-vaginal ejaculation latency time difference of one minute or more will be considered as efficient.	4 weeks
Secondary	Evaluation of IIEF-15 (International Index of Erectile Function) score compared to baseline	Increase in IIEF score will be considered as efficacy.	4 weeks
Secondary	Evaluation of premature ejaculation symptom scores compared to baseline	Increase in IIEF scores will be considered as efficacy.	4 weeks